menu
    • menu

    Company profile for Exelixis

    NEW Drugs in Dev: 17
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, caboz...
    Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tell the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ExelixisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    210 East Grand Avenue
    Telephone
    Telephone
    650 837 8194, (650) 837-7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exelixis Unveils Q1 2026 Financials And Corporate Update
    Exelixis Unveils Q1 2026 Financials And Corporate Update

    05 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7271401

    FIRSTWORD PHARMA
    05 May 2026
    Share Share
    Exelixis to Release Q1 2026 Financial Results on May 5
    Exelixis to Release Q1 2026 Financial Results on May 5

    21 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260421129215/en/Exelixis-to-Release-First-Quarter-2026-Financial-Results-on-Tuesday-May-5-2026

    BUSINESSWIRE
    21 Apr 2026
    Share Share
    Exelixis To Webcast Fireside Chats At March Investor Conferences
    Exelixis To Webcast Fireside Chats At March Investor Conferences

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224844659/en/Exelixis-to-Webcast-Fireside-Chats-as-Part-of-Upcoming-Investor-Conferences-in-March

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    Exelixis Unveils 2025 Financials, Corporate Update
    Exelixis Unveils 2025 Financials, Corporate Update

    10 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260210781065/en/Exelixis-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-Corporate-Update

    BUSINESSWIRE
    10 Feb 2026
    Share Share
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Exelixis to Report Q4, FY 2025 Results on Feb. 10
    Exelixis to Report Q4, FY 2025 Results on Feb. 10

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127808059/en/Exelixis-to-Release-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-on-Tuesday-February-10-2026

    BUSINESSWIRE
    27 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search